Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-825 in diffuse cutaneous systemic sclerosis
NL-OMON49927Phase 2Withdrawn
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fipaxalparant in systemic sclerosis (SSc) (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change in forced vital capacity percent predicted. Planned start Nov 2021; status: withdrawn.
02
Drugs
fipaxalparant
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON49927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49927.